Introduction
In utero gene therapy could be effective in treating certain genetic diseases that affect the fetus before birth. Timely introduction of transgenes into embryonic tissues may significantly reduce prenatal morbidity and mortatlity of such genetic diseases.
Various approaches to fetal gene therapy have previously been evaluated and discussed. Viral vectors such as retroviral 1 and adenoviral or adeno-associated viral (AAV) 2 vectors have been the mode of transfection most commonly adopted in fetal gene therapy, but are generally considered difficult to manipulate. An alternative transfection method is liposome-mediated delivery of plasmid vectors, which does not require specialized materials or knowledge of special vectors. In adult mice, in vivo experiments using cationic liposomes as DNA transfection reagents were initially reported as inefficient. 3 Several groups, however, are now reporting successful delivery of plasmid DNA into adult mice by tail vein injection. [4] [5] [6] Liposome-mediated in vivo transfection has recently begun to gain attention as a good alternative to viral vectors, and may also be a good mode of transfection in fetal gene transfer.
Several routes for gene delivery into mammalian embryos have previously been proposed. They include intrauterine injection into the fetus, 7 placenta, [8] [9] [10] amniotic cavity, 1, 11 yolk sac vessel 12 and umbilical cord. 13 For example, efficient in utero gene delivery to the circulation of mid-gestational murine fetuses has been achieved by direct injection into the yolk sac vessel. 12 Ultrasoundguided transcutaneous intra-umbilical injection has been applied to gene transfer to the circulation of fetal sheep. 13 Unfortunately, with these methods, gene delivery is laborious since each embryo has to be treated individually, or the abdomen of each pregnant female requires incision. Additionally, transduction is found in very limited tissues, such as the regions peripheral to the site of injection in the case of direct injection into the embryo, or surface tissues in the case of intra-amniotic injection.
Alternatively, the introduction of plasmid DNA into the circulation of pregnant mice has been proposed by Tsukamoto et al 14 as a different route for fetal gene delivery. Tsukamoto et al 14 demonstrated that with this simple technique, a wide variety of internal tissues of mid-gestational fetuses (treated at E 8.5) was transfected by exogenous plasmid DNA. Furthermore, using this technique all of the treated embryos at embryonic day (E) 8.5 were transfected. 14 There are some major shortcomings concerning this method including loss of vector DNA to maternal tissues and undesirable gene delivery to the mother. However, there also are merits such as the ability to transfect multiple embryos and a variety of embryonic tissues in one treatment and requirement of neither skills in handling of viral DNA, nor surgical dissection. To our knowledge, however, this technique has been assessed in only two reports so far. Tsukamoto's group reported that concerning this method, DMRIE-C (GIBCO BRL) is the best reagent, so far examined, in delivering plasmid DNA to mouse fetuses in vivo. 15 Okuda et al 16 demonstrated that this method can be applied to transplacental genetic immunization of mid-gestational murine fetuses.
Our aim in the present study is to test whether injection of liposome/plasmid complexes into pregnant mice is an effective method for gene delivery to fetuses. If this method proves effective, our next focus will be to produce disease-model mice by introducing foreign DNA into fetuses, or rescue abnormal phenotypes in genetic mutants such as knock-out mice and spontaneous mutants. In a previously proposed system based on direct delivery of a plasmid expression vector into target cells or tissues, transgene expression was transient, therefore the transgene could not be maintained after cell divisions. Alternatively, since transient Cre activity could bring about a permanent genomic alteration in a cell and the change can be inherited by all of the cell's progeny, 17 the Cre-loxP system appeared to be suitable for our purpose. We thus chose the Cre-loxP system to assess the efficacy of gene delivery via maternal tail vein to fetuses.
For our assay, we used CETZ-17 transgenic mice 18 as recipients of exogenous DNA. CETZ-17 transgenic mice carry between two and three copies of transgenes consisting of the cytomegalovirus enhancer and chicken ␤-actin promoter (termed 'CAG') 19 , loxP-flanked enhanced green fluorescent protein (EGFP) cDNA and chloramphenicol acetyltransferase (CAT) gene, and the LacZ gene (encoding the ␤-galactosidase gene) (Figure 1a ). When Cre expression vectors are taken up and expressed in CETZ-17 fetal cells, the loxP-flanked EGFP/CAT sequence in the CETZ-17 transgene is excised and the downstream LacZ gene becomes active under the control of the CAG promoter ( Figure 1a) . 18 Once recombination occurs, LacZ expression persists through fetal development, thus enabling lineage analysis of transduced cells. 18 As a transfection reagent for in vivo gene delivery, we used a non-liposomal lipid, FuGENE6 (No. 1814 443, Boehringer Mannheim, Mannheim, Germany) since we found that FuGENE6 markedly enhanced gene transfer of LacZ reporter plasmid in an in vitro cell culture system using F9 teratocarcinoma cells among commercially available lipids tested (including Lipofectin (GIBCO/Life Technologies), DOSPER (Boehringer Mannheim) and SuperFect (Qiagen, Hilden, Germany)) (unpublished data). Furthermore, it had several advantages over some other lipids, such as low toxicity 20 and the ability to transfect under serum conditions. 21 When the Cre expression vector was mixed with FuG-ENE6 and intravenously injected into pregnant CETZ-17 females at E 11.5 to 13.5, 10-50% of fetuses exhibited LacZ activity and expression of Cre mRNA. In contrast, embryos dissected from females injected at E 4.5 to 10.5 failed to exhibit distinct LacZ activity. However, polymerase chain reaction (PCR) analysis revealed small amounts of Cre DNA and low frequencies of Cremediated recombination of the CETZ-17 transgene in embryos treated at E 6.5 to 10.5. As revealed by intravenous injection of trypan blue (TB) and fluorescence-labeled DNA, substances injected into maternal blood appeared to reach embryos, but most seemed to be trapped in cells of the visceral endoderm lineage. Introduction of genes into murine fetuses by injection into the maternal circulation may be a promising method, but is still inefficient, and needs substantial improvement for practical use. Possible ways of improving this system are discussed.
Results
Cre-mediated expression of LacZ reporter gene in fetuses and adult tissues of CETZ-17/CAG-Cre double transgenic mice We previously described the LacZ activity of preimplantation embryos (four-cell embryos, morulae and blastocysts) of CETZ-17 transgenic mice microinjected with pCAG/NCre DNA at the two-cell stage. 18 However, it remained unclear whether expression of LacZ continued during the post-implantation stages and in adulthood. In a preliminary test, we mated CETZ-17 females with CAG-Cre males 22 and stained their offspring (fetuses at E 10.5 and adult tissues) with X-gal. As shown in Figure 1b , the double transgenic fetuses, but not the CETZ-17 fetuses, exhibited LacZ activity. Organs (including skeletal muscle, heart and pancreas) of double transgenic adult mice exhibited LacZ activity, while those of CETZ-17 mice did not. These findings indicate that the Cre-loxP system using CETZ-17 transgenic mice works well in the post-implantation and adult stages. Notably, localization of blue deposits in each organ of the double transgenic mice was mosaic: staining in some cells was strong, while some was weak. This appears to be due to the cell specificity of CAG promoter, although it is known to be expressed in a variety of cells. 23, 24 In transgenic mice carrying CAG promoter-driven expression units, mosaic expression of target genes (or cDNAs) has been observed in many organs including the pancreas, 24 ,25 skeletal muscle 24, 26 and heart. 26 Distinct LacZ staining in fetuses from pregnant females receiving intravenous injection of pCAG/NCre/FuGENE6 complexes at E 11.5 and thereafter We introduced pCAG/NCre/FuGENE6 complexes intravenously into pregnant CETZ-17 females at E 4.5-13.5. At the time-points indicated in Materials and methods, fetuses were dissected from the females and subjected to histochemical staining for LacZ activity. When fetuses from pregnant females injected at E 11.5-13.5 were stained with X-gal, 10-50% of fetuses examined exhibited clear blue deposits in the heart, head and vertebral region (Table 1 ; left fetuses in Figure 2a and b). Histological sectioning of a LacZ-positive fetus treated at E 12.5 (left fetus in Figure 2b ) revealed blue deposits in a variety of tissues throughout the body (left fetus in Figure 2c ). When observed in more detail, blue deposits were found in the choroid plexus (Figure 2d ), subventricular zone of the fourth ventricle (Figure 2e ), heart and pericardium (Figure 2f ), neural tube ( Figure 2g ) and spinal ganglia (Figure 2h ). Histological sectioning of another LacZ-positive fetus corresponding to E 13.5 (fetus on the left in Figure 2a ) revealed a similar distribution of blue deposits, although staining of the heart was significantly reduced (data not shown). Notably, levels of LacZ activity appeared to be very low or absent in the lungs and livers of these LacZ-positive specimens. This is probably due to the nature of the CAG promoter itself; activity of transgenes driven by CAG promoter was reduced in the lungs and livers in mice. 24 Fetuses given the pCAG/NCre/FuGENE6 complex at E 4.5-10.5 did not exhibit overt LacZ activity. Control fetuses given PBS(Ϫ) (right fetuses in Figure 2a , b, c) injections or PBS(Ϫ) containing FuGENE6 (without DNA) at E 11.5-13.5 (data not shown) were completely negative for LacZ activity. Untreated fetuses from non-transgenic females at E 11.5-13.5 also exhibited no overt LacZ activity (data not shown). Judging solely from histochemical staining, transfer of substances (including plasmid DNA molecules) in maternal blood to the fetal side appears to commence at around E 11.5. Interestingly, the placenta Gene Therapy becomes fully developed and functional just before this stage (at E 9-10).
CETZ-17 fetuses treated with pCAG/NCre/FuGENE6 complexes at E 6.5-13.5 have a recombined form of the CETZ-17 transgene
We next examined by PCR whether Cre-mediated recombination had occurred in the LacZ-positive CETZ-17 fetuses. If the injected vector DNA causes Cre-mediated excision in CETZ-17 fetuses, a recombined form of the CETZ-17 transgene (CZ) should be generated, and should easily be detected by PCR with the ␤-gl-1/␤gal-RV primer set (744-bp products; Figure 1a ). As seen in the upper panel of Figure 3a , distinct bands were yielded by PCR in the LacZ-positive fetus (indicated as '+') treated Table 1 Numbers of LacZ-positive and NCre DNA-positive fetuses after injection of pCAG/NCre DNA/FuGENE6 complexes into pregnant CETZ-17 females at E 4.5 to 13. Fetuses treated at E 4.5 to 8.5 were all sampled on E 10.5 for staining with X-gal and DNA analyses. Fetuses treated at E 9.5 to 13.5 were sampled 1 day after DNA injection. b Only fetuses exhibiting clear blue deposits throughout their bodies and clearly distinguishable from intact untreated fetuses were scored as LacZ-positive fetuses. Fetuses which exhibited faint staining and were indistinguishable from untreated fetuses were considered LacZnegative fetuses. c PCR for detection of NCre gene was performed using the Cre-2S/Cre-2RV primer set (see Figure 1a ). * ND, not determined.
at E 12.5. The other samples, which were apparently negative for LacZ staining (indicated as '-'), did not produce any visible band corresponding to CZ. However, after blotting and hybridization of the gel in the upper panel using the 5' portion of the LacZ gene as probe, CZ was detectable in most of the LacZ-negative embryos treated at E 6.5, 9.5 and 12.5 (middle panel of Figure 3a ). Negative controls including tail DNA from uninjected B6C3F1 adult mice (middle panel of Figure 3a ) and mock injected fetal samples from females injected with PBS(Ϫ) or PBS (Ϫ) and FuGENE6 (data not shown) did not exhibit CZ even after Southern blotting (data not shown). These findings suggest that (1) there is no CETZ-17 recombination in the absence of transfection with the Cre expression construct, and (2) there is a good correlation between LacZ activity and generation of CZ; in other words, increased production of CZ leads to elevated LacZ activity, and can be identified histochemically. These findings also imply that the Cre expression vector did in fact cause Cre-mediated recombination in embryos as early as E 6.5, however LacZ expression failed to reach a detectable level, probably due to a very low amount of recombined DNA.
Detection of NCre mRNA in CETZ-17 fetuses after intravenous injection of pCAG/NCre/FuGENE6 complexes at E 12.5
To confirm that NCre is expressed in the treated fetuses, RNA from fetuses of females injected with pCAG/NCre/FuGENE6 complex at E 12.5 and sampled at E 13.5 was subjected to reverse transcription-PCR (RT-PCR). Results are shown in Figure 3b . Two of 12 samples examined exhibited distinct 403-bp bands corresponding to NCre mRNA (Figure 3b ), indicating that the Cre expression vector was incorporated into embryos and in fact expressed. In the samples positive for NCre mRNA, additional bands were seen at 1.2 kb and 0.7 kb. The former is believed to be the PCR product of pCAG/NCre DNA, which had contaminated the samples during isolation of RNA. The latter are thought to be non-specifically amplified products. These findings imply that the samples negative for NCre mRNA had no, or negligible amounts of NCre DNA.
Embryos can incorporate exogenous DNA after intravenous DNA injection at the egg cylinder stage (E 6.5)
We performed PCR using the Cre-2S and Cre-2RV primer set ( Figure 1a ) to see whether pCAG/NCre DNA is detectable even in some of the LacZ-negative embryos from mice injected with pCAG/NCre/FuGENE6 complexes. As seen in Table 1 and Figure 4a , DNA was undetectable by PCR in most embryos of mice injected at E 4.5 and 5.5. However, fetuses from females injected at E 6.5 possessed DNA with a frequency of 78.3%. Similar transduction of the exogenous DNA into fetuses was observed in embryos from females injected with the DNA/lipid complex at E 7.5 to 12.5. These findings suggest that incorporation of exogenous DNA into embryos via blood flow from the mother commences at around E 6.5. As mentioned previously, CZ dramatically increased at E 11.5 and thereafter. Based on this observation, we hypothesized that DNA transfer also increased at E 11.5. To test this possibility, we examined average copy numbers of pCAG/NCre in fetal cells. Since genomic DNA from samples fixed with 4% paraformaldehyde (PFA) and stained with X-gal are resistant to digestion with restriction enzymes generally used for genomic Southern blot hybridization analysis, we estimated copy numbers by PCR of the NCre gene. DNA samples from fetuses treated at E 9.5, 10.5 and 12.5 were screened by PCR amplification of a 300-bp fragment of pCAG/NCre DNA with primers Cre-2S/Cre-2RV (Figure 1a) , as shown in Figure 4a . Several of these DNA samples were diluted and subjected to PCR with copy controls. Band patterns of amplified fetal DNA were compared with those of the copy controls. The results are shown in Figure 4b . All five fetuses treated at E 9.5 possessed the exogenous DNA at approximately 0.1 copies per cell. Two of four fetuses treated at E 10.5 possessed the pCAG/NCre DNA at approximately 0.2-2 copies per cell. All of four fetuses 
heart and vertebral region (left fetuses in (a, b)). No staining was noted in mock-injected (with PBS(Ϫ)) CETZ-17 control fetuses (right fetuses in (a, b)). Cryostat sections of specimens in (b) are shown in (c). In an X-gal-positive sample (left fetus in (c)), distinct staining for LacZ was observed, whereas in the control fetus no LacZ staining was observed (right fetus in (c)). Panels (d) to (h) correspond to regions in the left fetus in (c), where cells exhibited distinct LacZ staining. Marked LacZ staining was seen in the epithelial layer (indicated by arrows) of the posterior choroid plexus (d), subventricular zone of the fourth ventricle (indicated by arrows) (e), myocardium (f), ventral portion of the neural tube (indicated by arrows) (g) and cells of the spinal ganglia (indicated by arrows) (h). A, atrial wall of the heart; C, central canal of the neural tube; E, epithelial layer of the choroid plexus; G, spinal ganglion; P, pericardium; V, ventricular wall of the heart; VB, cartilage primordium of vertebral body; IV, lumen of the fourth ventricle.
treated at E 12.5 had between one and five copies per cell. This indicates that E 12.5 fetuses take up exogenous DNA from maternal blood more readily than fetuses at E 9.5 and 10.5. The present finding is in good agreement with our previous finding that significant LacZ activity can only be detected in fetuses treated after E 11.5.
Gene Therapy
Trypan blue and fluorescence-labeled DNA are mainly concentrated in the visceral endoderm or yolk sac in egg cylinder to mid-gestational fetuses As mentioned above, plasmid DNA injected into tail veins of pregnant mice can be incorporated into embryos as early as at E 6.5. To further examine the fate of sub- stances in embryos in egg cylinder and mid-gestational stages, we injected trypan blue (TB) into the tail veins of pregnant B6C3F1 females at E 5.5, 8.5, 9.5 and 11.5. When TB was injected into females at E 5.5, blue staining was localized in the decidua surrounding embryos and visceral endoderm (VE) layer, especially the region facing the extra-embryonic ectoderm (Ex Ect) (Figure 5a and b) . When pregnant females at E 8.5 to 11.5 were injected with TB, TB was confined to the yolk sac (fetuses on the left in Figure 5c -f). Localization was especially marked in the region of yolk sac proximal to the fetus (fetus on the left Table 1 in Figure 5e ). Untreated embryos were negative for blue staining (fetuses on the right in Figure 5c-f) .
TB is known to be taken up by absorptive pinocytosis and trapped in cells of the visceral endoderm lineage in rodents. 27, 28 Since TB possibly does not go beyond the VE, we further examined whether fluorescence-labeled DNA/lipid complexes exhibit a distribution similar to that of TB. Fluorescence-labeled HaeIII-digested pBluescript SK(Ϫ) plasmid vector fragments were column-purified (Figure 6a ) and mixed with FuGENE6. The resulting complexes were injected into E 6.5 pregnant mice. Similar to TB, labeled DNA collected mainly in the VE layer proximal to the ectoplacental cone 1 day after injection (Figure 6b ). 
. All embryos were dissected 1 day after treatment. (a, b) E 6.5 egg cylinders from female mice treated with TB (a) or PBS(Ϫ) (b). Decidua cut open to expose egg cylinders (left in (a, b)) and egg cylinders isolated from the decidua (right in (a, b)). In the embryo treated with TB, the dye was localized in the deciduum surrounding the embryo (indicated by arrows in (a)) and visceral endoderm layer, especially the region proximal to the extra-embryonic ectoderm (indicated by arrowheads in (a)). No blue deposit was noted in either the decidua or embryos in controls treated with PBS(Ϫ). EPC, ectoplacental cone; E Ect, embryonic ectoderm; Ex Ect, extraembryonic ectoderm. (c) E 9.5 embryos treated with TB (left) or PBS(Ϫ) (right). TB was localized throughout the entire yolk sac of the embryo treated with TB. (d) E 10.5 embryos treated with TB (left) or PBS(Ϫ) (right). TB was mainly localized in yolk sac, but not in the embryo proper. (e, f) E 12.5 fetuses treated with TB (left) or PBS(Ϫ) (right). They are shown in their yolk sacs (e) or denuded from their yolk sacs (f). TB was mainly localized in the yolk sac proximal to the placenta.

Discussion
Tsukamoto et al 14 first demonstrated that plasmid DNA carrying the LacZ gene complexed with cationic lipids (DOGS) and intravenously injected into pregnant females at E 8.5 was transferred to embryos. The same group later compared the transfer efficiencies of different transfection reagents in mid-gestational embryos. 15 However, to our knowledge, very few studies have been done based on this method.
In the present study, we used a Cre-loxP system to perform gene transfer to murine fetuses by injection of plasmid DNA into the maternal circulation. Although we successfully repeated the results of Tsukamoto et al, 14 there were several differences between their findings and ours. First, Tsukamoto et al 14 demonstrated that DNA injected into females at E 8.5 transferred efficiently to embryos, while in our system efficient transfection commenced at E 11.5. Second, Tsukamoto et al 14 achieved staining of all E 8.5 embryos, while in our study only 10 to 50% of E 11.5-13.5 fetuses were stained, as evaluated by histochemical staining for LacZ activity (see Table 1 ; Gene Therapy Figure 2 ). Third, in their study, LacZ products were observed mainly in the heart, limb buds and pancreatic bud of E 10.5 fetuses, whereas in our specimens the heart, subventricular zone of the fourth ventricle, neural tube and spinal ganglia were the most clearly stained. These differences may be partly due to the amount of DNA introduced (133 g versus 20 g of DNA/mouse), the transfection reagent used (DOGS versus FuGENE6) or promoters used (SV40 and human ␤-actin-based promoters versus cytomegalovirus enhancer/chicken ␤-actinbased promoter). In our preliminary test, administration of 133 g of plasmid DNA mixed with 260 l of FuG-ENE6 was found to be toxic to pregnant female mice, since they often aborted or suddenly died (unpublished data). Furthermore, Tsukamoto et al 14 used normal hybrid female mice (B6C3F1 females × B6 males), into which a LacZ expression vector was introduced, while we used CETZ-17 transgenic mice into which a Cre expression vector was introduced. In the former case, transient expression of LacZ gene in embryos is required for LacZ activity, while in the latter case Cre-mediated recombination in the integrated CETZ-17 transgene is Gene Therapy
Figure 6 Intravenous injection of fluorescence-labeled DNA fragments (HaeIII-digest of pBluescript SK(Ϫ))/lipid complexes into pregnant females at E 6.5. (a) Agarose gel electrophoresis of Alexa Fluor 488-labeled DNA fragments before injection. The labeled DNA fragments before purification (lane 1) and after purification (lane 2) were run on 2% agarose gels and photographed under UV illumination (indicated as 'Before staining with EtBr'). Before purification, a few clusters of free fluorophores (arrowheads) and fluorescent DNA fragments were observed, but after purification only fluorescent DNA fragments were seen. This gel was then stained with EtBr (indicated as 'After staining with EtBr'). The two lanes contained the EtBr-stained bands at the same position. m, 100-bp DNA ladder. (b) Egg cylinder at E 7.5 after injection of Alexa Fluor 488-labeled DNA (left column) or no injection (right column). A cluster of fluorescence-labeled DNA fragments (arrowhead) was observed at the boundary between the ectoplacental cone (EPC) and the extraembryonic ectoderm (Ex Ect) in the sample treated with labeled DNA, but no fluorescence was noted in the control samples. Upper panels indicate figures taken under light illumination, and lower panels indicate figures taken under UV illumination.
required. Although our initial intent in using the Cre-loxP assay system was to initiate continuous expression of LacZ throughout development, it may require a relatively high amount of Cre gene expression in embryos. In this respect, our system may require further improvement to achieve effective gene transfer to fetuses.
We observed the highest LacZ activity in tissues such as the heart, subventricular zone of the fourth ventricle in brain, neural tube and spinal ganglia of the CETZ-17 fetuses after treatment with pCAG/NCre/FuGENE6 complexes at E 11.5 (see Figure 2d-h) . Interestingly, the cells exhibiting the highest LacZ activity were not necessarily the cells facing blood vessels; for example in the heart, we noted mottled expression of LacZ in the myocardium rather than localized expression in the endocardium, while in the aorta, we found no LacZ staining in cells. These findings were unexpected, because we initially believed that cells adjacent to blood vessels would exhibit high levels of LacZ activity. There could be various reasons for this pattern of LacZ activity, which may include the following: (1) the level of transcriptional/translational activity occurring in each cell is different; (2) the transfection efficiency of DNA/FuGENE6 complexes may vary in different tissues and in each gene administration; and (3) although the CAG promoter is considered a ubiquitous promoter, it may function better in some types of cells than in others.
In this study, we found that the amount of plasmid DNA transferred from maternal blood to the embryo proper was generally low (see Figure 4) , and that fluorescence-labeled DNA/FuGENE6 complexes transferred from the maternal blood were trapped in the VE at E 6.5 (see Figure 6 ). Based on the present findings, we postulated a possible mechanism of gene transfer via tail vein to egg-cylinder and mid-gestational mouse fetuses (Figure 7) . At E 5.5 to 9.5, when the placenta is immature, nutrients including lipids are known to be taken up by the VE or yolk sac, and then transported to embryos by direct diffusion or vitelline circulation. 29, 30 Similarly, DNA/lipid complexes in maternal blood may be transferred to embryos via the maternal blood vessels in the deciduum and transferred to the VE, as depicted by arrowheads in Figure 7a . Subsequently, most of the DNA/lipid complexes may be trapped in the VE lineage, but a small amount may be taken up by the vitelline circulation, and transported to the embryo proper. At E 10.5 to 13.5, transfer of nutrients commences at the placenta. As shown by arrowheads in region A of Figure 7b , some of the plasmid DNA/lipid complexes may be transferred to the umbilical vein at the placenta, and then into the embryonic circulation. The start of placental circulation may account for increased transfer of DNA at E 11.5. However, as shown by arrowheads in region B in Figure  7b , some of the plasmid DNA/lipid complexes may also enter the blood vessels of the decidua. While some exogenous DNA may be transferred to the embryo via the vitelline veins, most may be trapped at the yolk sac, especially the portion proximal to the placenta. To our knowledge, no other group has reported that the yolk sac circulation may function as a possible route in the trans- fer of DNA/lipid complexes from the maternal circulation to fetuses.
Tsukamoto et al 14 and Ochiya et al 15 argued that efficiency of fetal gene transfer by injection into the maternal circulation using the transfection reagent DOGS was greatly reduced, because most of the DNA was trapped in the maternal lungs. We believe that trapping of exogenous DNA at the yolk sac or VE is another barrier that reduces the efficiency of gene transfer from the maternal circulation to embryos. However, this system may provide a plethora of new possibilities in gene transfer to the VE and yolk sac. Genes expressed in VE and yolk sac have recently begun to gain attention. There are genes in the VE that play vital roles in nourishing embryos with lipids and amino acids, 29, 30 angiogenesis and hematopoesis, 31, 32 and head induction and anteriorposterior axis formation. 33, 34 Gene transfer in pregnancy may be useful in the analysis of the in vivo function of these genes.
In the present study, the amount of exogenous plasmid DNA taken up by post-implantation fetuses at E 9.5 and 12.5, was estimated to be approximately 0.1 and between one and five copies per cell, respectively. The copy numbers obtained could be an underestimation, since the copy number controls were subjected to PCR in the absence of genomic DNA. Therefore the copy number controls could be amplified more efficiently than the fetal samples. Despite the possibility of this underestimation, the amount of incorporated vector DNA was still insuf-ficient for strong expression of the plasmid. To improve transfection efficiency, several measures, including choice of appropriate transfection reagents and use of other transfection methods (in conjunction with transfection reagents), should be taken. Many transfection reagents are now commercially available, each with its own unique characteristics. Ochiya et al 15 employed several transfection reagents to assess the transfection efficiency of embryos, and found that DMRIE-C (Life Technologies) was the best reagent for gene transfer in this system. There have been other reports that incorporation of cholesterol into cationic lipids improves transfection efficiency in vivo. 5, 6, 35, 36 We are also contemplating a novel method: the injection of plasmid/lipid complexes into the maternal circulation and subsequent in vivo electroporation (EP) 37 to the uterus. In vivo EP may aid the transfer of DNA to embryos from the surrounding tissues.
In summary, as the first step to developing a simple and efficient gene transfer system to post-implantation fetuses, we injected circular Cre expression plasmid DNA/lipid conjugates into the tail veins of E 4.5-13.5 pregnant females carrying a transgene consisting of a CAG promoter, loxP-flanked EGFP/CAT sequences and the LacZ reporter gene. We found that LacZ activity, which can be evidence for successful gene transfer into embryos, was detectable only when injection was conducted at E 11.5 and thereafter. PCR analyses revealed that a very small amount of plasmid DNA could enter embryos even at the egg cylinder stage. Findings from the intravenous injection of TB and fluorescence-labeled DNA/FuGENE6 complexes indicate that there is a previously undescribed transfer route via the vitelline circulation, but most substances in the maternal blood that are transferred to the fetus appear to be trapped in the yolk sac or its precursor, the VE. Our system is still inefficient and is still at the level of basic research. However, if improved, gene transfer via maternal tail vein may be useful as a method for fetal gene therapy and in the study of the molecular mechanisms of embryogenesis in the early to mid-gestational stages.
Materials and methods
Mice
For introduction of a Cre expression vector, the CETZ-17 transgenic line 144-5 18 was used. Since transgenic offspring of the 144-5 line exhibit EGFP fluorescence on their surfaces such as skin, they could easily be selected by observing fluorescence under a stereomicroscope (SZX12, Olympus) with an attached UV illuminator. Pregnant heterozygous CETZ-17 transgenic females (aged 8 to 15 weeks) were obtained by natural mating with heterozygous CETZ-17 males. For induction of superovulation, females were given eCG-hCG 48 h apart. For all matings, the day the plug was recognized was designated as E (embryonic day) 0 of pregnancy.
B6C3F1 (CLEA Japan, Tokyo, Japan; a hybrid between C57BL/6N and C3H/HeN) mice, aged 8 to 15 weeks, were used for intravenous injection of TB or fluorescencelabeled DNA/FuGENE6 complex, as described below.
Mice were kept on a 12 h light/12 h dark schedule (lights on from 07.00 h to 19.00 h) and allowed food and water ad libitum. Experiments were carried out in accordance with the Guide for the Care and Use of Laboratory Animals at Tokai University.
Production of double transgenic offspring by mating of CETZ-17 with CAG-Cre mice
To confirm the viability of the Cre-loxP system in CETZ-17 transgenic mice, we obtained double transgenic E 10.5 fetuses and 8-10-week-old adult mice by crossing heterozygous CETZ-17 female mice with homozygous CAGCre males expressing the Cre gene ubiquitously. 22 In the fetuses, the CETZ-17 and CAG-Cre transgenes were detected by PCR of DNA from the yolk sac, which had been separated from fetuses upon dissection. Adult double transgenic mice were identified by PCR analysis of tail DNA. The CETZ-17 and CAG-Cre transgenes were identified using the 3'␤GAL-S/␤-gl-2RV and Cre-2S/Cre-2RV primer sets, respectively, as described below, and shown in Figure 1a . Organs (including heart, skeletal muscle and pancreas) of the adult mice and fetuses were subjected to histochemical staining for LacZ activity, as described below.
Preparation of plasmid vector and DNA/lipid complexes
To elicit ubiquitous expression of the injected Cre gene, we used pCAG/NCre plasmid DNA (Figure 1a) 18 in which expression of NCre protein is controlled by the CAG promoter. Note that the NCre vector has a nuclear localization signal at the 5' end of the Cre gene. 18 Solutions containing plasmid DNA/lipid complexes were prepared at volumes of 200 l/mouse. For each solution, 40 l of FuGENE6 (Boehringer Mannheim) was diluted with 60 l of phosphate-buffered saline without Ca 2+ and Mg 2+ (PBS(Ϫ)), pH 7.2, then added to 20 g of circular plasmid DNA dissolved in 100 l PBS(Ϫ) according to the manufacturer's protocol. The resulting DNA/lipid complex solutions were injected into the tail veins of pregnant CETZ-17 females at E 4.5 to 13.5, as described below. For mock injections with FuGENE6 (no DNA), solutions were made similarly to those of the DNA/lipid complex solutions, except that 100 l of plasmid solution was replaced with 100 l of PBS(Ϫ). For solutions containing fluorescence-labeled DNA/lipid complexes, 100 l of DNA fragments (less than 1 kb in size; 3 g in total) derived from HaeIII-digested pBluescript SK(Ϫ) vector DNA (Stratagene, La Jolla, CA, USA) were labeled with a ULYSIS Alexa Fluor 488 Nucleic Acid Labeling Kit (No. U-21650; Molecular Probes, Eugene, OR, USA). The labeled DNA fragments were column-purified according to the manufacturer's protocol to remove free fluorophores, run on a 2% agarose gel and subsequently viewed under UV illumination. FuGENE6 (6 l) diluted with 94 l of PBS(-) was then added to the DNA fragments, to form DNA/lipid complexes. The complexes were then injected into tail veins of pregnant B6C3F1 females at E 6.5.
Intravenous injection of plasmid DNA/lipid complex, TB or fluorescence-labeled DNA into pregnant females
The solutions (200 l/mouse) containing pCAG/NCre DNA/FuGENE6 complexes were injected into tail veins of unanesthetized pregnant CETZ-17 mice at E 4.5 to 13.5 with a 1-ml plastic disposable syringe (Terumo, Tokyo, Japan) fitted with a 27-gauge needle (Nipro, Osaka, Japan). Control fetuses were obtained from CETZ-17 females receiving intravenous injection of 200 l of PBS(Ϫ) or PBS(-) containing 40 l of FuGENE6 into pregnant CETZ-17 females (mock injection). Injections were performed at a speed of 200 l/8-10 s. Fetuses from females injected at E 4.5 to 8.5 were isolated at E 10.5. In cases in which mice were injected at E 9.5 to 13.5, fetuses were isolated 1 day after DNA introduction. The isolated fetuses were completely separated from yolk sacs, fixed with 4% paraformaldehyde (PFA) in PBS(-) at 4°C for 3-5 h, and subjected to histochemical staining with X-gal, as described below. Some of the LacZ-positive and LacZnegative samples were subjected to cryostat sectioning. The remaining samples were subjected to isolation of genomic DNA and subsequent PCR analysis.
Procedures for the introduction of TB (Trypan Blue Stain 0.4%, No. 15250-061, GIBCO BRL, Grand Island, NY, USA) (200 l/mouse) into pregnant B6C3F1 females at E 5.5, 8.5, 9.5 and 11.5 were similar to those for DNA/FuGENE6 complexes. Control fetuses were obtained by introduction of 200 l of PBS(Ϫ) into pregnant normal B6C3F1 females (mock injection). All of the treated mice were dissected 1 day after injection. For mice treated at E 5.5 and 8.5, decidua were removed from uteri of injected females, cut open to expose the embryos then fixed in 4% PFA dissolved in PBS(Ϫ) at 4°C for 3-5 h. The embryos were next dissected out from the decidua and photographed with a digital camera attached to a stereomicroscope. Fetuses from pregnant mice injected at E 9.5 and 11.5 were dissected with their yolk sacs, fixed in 4% PFA overnight and photographed. Several of the fetuses were removed from their yolk sacs and photographed. Fluorescence-labeled DNA/lipid complexes were injected into E 6.5 pregnant B6C3F1 females. One day after injection, the females were killed to isolate decidua containing the embryos. The isolated decidua were cut open to expose the embryos, fixed in 4% PFA dissolved in PBS(Ϫ) at 4°C for 3-5 h and subsequently photographed under UV illumination.
PCR analysis
Isolation of genomic DNA from fetuses was performed as previously described 38 with several modifications. 39 Fetal samples, which were fixed with 4% PFA and treated with X-gal, were crushed under a slide glass by applying slight pressure, and then lysed with proteinase K and pronase E. A few DNA samples from fetuses dissected at E 13.5 exhibited DNA degradation, and were immediately discarded.
PCR amplification reactions were performed in a total volume of 10 l, containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 0.25 mM each of dATP, dCTP, dGTP and dTTP, 1 mM primers, 1 g genomic DNA and 0.5 units Taq polymerase (TaKaRa Taq; No. R001A, Takara Shuzo, Tokyo, Japan). Reactions were performed in a Perkin Elmer DNA Thermal Cycler (480) with the following conditions: 94°C for 5 min followed by 94°C for 1 min, 56°C for 1 min and 72°C for 4 min for 40 cycles.
One set of primers, Cre-2S/Cre-2RV (Figure 1a) , yields 300-bp fragments from the 3' region of the NCre gene, and was used to identify the pCAG/NCre DNA introduced into the maternal tail vein. Cre-2S (5'-GAT CCG AAT AAC TAC CTG TTT-3') corresponds to the 5' portion of the Cre gene sequence 40 from nucleotides 1441 to 1461, and Cre-2RV (5'-TGT TTC ACT ATC CAG GTT ACG-3') corresponds to the 3' region of the Cre gene sequence 40 from nucleotides 1740 to 1720. Another set of PCR primers, 3'␤GAL-S/␤-gl-2RV (Figure 1a) , yields 281-bp fragments (termed lacZ3'; Figure 1a ) from the 3' portion of the LacZ gene in pCETZ-17, and was used for Fetuses with blue deposits throughout their bodies were considered positive for LacZ activity. Organs from double transgenic mice were considered LacZ-positive only when there was apparently more staining in those of the double transgenic mice than those of the CETZ-17 control mice.
CETZ-17 fetuses from mothers treated with pCAG/NCre DNA/FuGENE6 conjugates were photographed, and then inspected for EGFP fluorescence under UV illumination. Fluorescent fetuses (transgenic fetuses) were then selected, and used for further analysis. Most of the CETZ-17 fetuses were subjected to lysis for genomic DNA isolation, as mentioned previously. Some of the remaining specimens were fixed again with 4% PFA at 4°C for more than 1 week and subjected to cryostat sectioning.
Cryostat sectioning of CETZ-17 fetuses
Fetuses treated with pCAG/NCre DNA/FuGENE6 at E 11.5 and 12.5, and their controls were dehydrated in a sucrose series in PBS(Ϫ) (5% for 24 h, 10% for 24 h and 20% for 48 h) and then embedded in OCT compound (Tissue-Tek, No. 4583; Miles Scientific, Naperville, IL, USA). The embryos were subjected to cryostat sectioning at 10-14 m/section.
